|
|
|||
|
||||
OverviewEndocannabinoids, the latest volume in the International Review of Neurobiology series is a comprehensive overview of the state-of-the-art research into the neurobiology of migraines. It reviews the current knowledge and understanding in the field, and provides a starting point for researchers and practitioners entering the field. Full Product DetailsAuthor: Loren Parsons (The Scripps Research Institute, CA, USA) , Matthew Hill (University of Calgary, Alberta, Canada)Publisher: Elsevier Science Publishing Co Inc Imprint: Academic Press Inc Volume: 125 Dimensions: Width: 15.20cm , Height: 2.30cm , Length: 22.90cm Weight: 0.700kg ISBN: 9780128012789ISBN 10: 0128012781 Pages: 352 Publication Date: 27 November 2015 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Manufactured on demand We will order this item for you from a manufactured on demand supplier. Table of ContentsReviewsAuthor InformationMatthew Hill is an Assistant Professor in the Departments of Cell Biology and Anatomy and Psychiatry at the Hotchkiss Brain Institute at the University of Calgary (Canada). He was trained in Behavioral Neuroscience and Psychoneuroendocrinology at the University of British Columbia and did postdoctoral training in the laboratory of Dr. Bruce McEwen at the Rockefeller University. Dr. Hill’s research has helped to reveal the critical role, and neural circuits through which, endocannabinoid signaling regulates acute responsiveness and adaptation of the stress response, both at the neuroendocrine and behavioral level. Further, his research has demonstrated how chronic stress can compromise endocannabinoid function, identifying this system as target for both the pathophysiology and treatment of stress-related mood and anxiety disorders. This research program is funded by CIHR, NSERC and Brain Canada. Dr. Hill has done consulting with Health Canada regarding their information document for health care professionals providing information on cannabis, as well as in industry where he has consulted with both Pfizer and Johnson & Johnson regarding their endocannabinoid research programs and potential applications to stress-related psychiatric illnesses. Tab Content 6Author Website:Countries AvailableAll regions |